Do kidney, liver, and gastrointestinal pathways help clear metals and mycotoxin metabolites?

Clearance of metals and mycotoxin metabolites is distributed across renal, hepatic, and biliary–intestinal pathways, but the dominant route—and the consequence of impaired function—varies substantially by compound.

Clinical and pharmacokinetic evidence

• Renal elimination is important for absorbed lead and inorganic mercury; cadmium is chiefly eliminated in urine despite prolonged tissue retention. In controlled human deoxynivalenol (DON) studies, approximately 64–70% of exposure was recovered in urine within 24 hours, with an elimination half-life of about 4 hours, largely after glucuronidation.
• Hepatic metabolism facilitates clearance of mycotoxins by producing excretable conjugates. DON glucuronidation is well characterized. Aflatoxin B1 metabolism yields urinary biomarkers, while biliary/fecal elimination is supported mainly by animal data.
• Biliary–fecal clearance is especially important for methylmercury, whose principal route is bile to feces. Ochratoxin A (OTA) is eliminated through both urine and feces.

Reduced function and persistence

• Reduced eGFR is associated with lower urinary arsenic, cadmium, and mercury; blood cadmium is higher in severe chronic kidney disease. These patterns support impaired renal clearance as a contributor to increased internal concentrations, although exposure-related kidney injury can also contribute.
• OTA illustrates a credible persistence mechanism: a slow-phase plasma half-life of 35.55 days was reported in one volunteer, consistent with strong albumin binding, low renal clearance, tubular reabsorption, biliary secretion, and possible enterohepatic cycling.
• Effects of hepatic dysfunction, reduced bile flow, or altered intestinal handling cannot be assumed across all toxins. Fecal measurements may also represent unabsorbed ingested material rather than elimination after systemic absorption.

Mechanistic considerations

• Urinary clearance reflects not only filtration but also tubular secretion and reabsorption.
• For lead, release from bone stores can sustain blood lead after external exposure stops; persistent blood levels therefore do not necessarily indicate ongoing exposure.

Bottom line

• Kidney, liver, and gastrointestinal routes all contribute to clearance, but reduced function plausibly raises exposure or prolongs persistence only in a compound-specific manner—most clearly for renal-dependent compounds and potentially OTA.